SCHEMBL3274290

SCHEMBL3274290

Cn1cc(S(=O)(=O)OCc2ccccc2)nc1-c1ccc(C(N)=O)cc1Br

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.36
AR P10275 2/20 0.35
JAK2 O60674 3/20 0.34
JAK1 P23458 3/20 0.34
TYK2 P29597 3/20 0.34
JAK3 P52333 3/20 0.34
CHEK2 O96017 2/20 0.34
BRD4 O60885 2/20 0.34
PTGER1 P34995 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
P2RX7 Q99572 1/20 0.33
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303615 0.85 CHEK2 (0.37) PARP10CHEK2PTGER1KDM4EMEN1
SCHEMBL2211111 0.79 TPSAB1 (0.42) PARP10KMT2ANPC1ALDH1A1RAB9A
SCHEMBL3376403 0.77 TP53 (0.42) PARP10KDM4EALDH1A1LMNAMAPT
SCHEMBL3378150 0.76 PDE2A (0.34) MEN1KMT2A
SCHEMBL3378338 0.76 CNR1 (0.37) LMNA
SCHEMBL454747 0.65 F7 (0.35) ARNPC1RAB9ASMN1; SMN2
SCHEMBL27510595 0.64 PARP10 (0.50) PARP10
SCHEMBL1966566 0.64 LMNA (0.44) CHEK2KDM4EMEN1KMT2AALDH1A1
SCHEMBL303821 0.62 LMNA (0.58) MEN1KMT2AALDH1A1LMNA
SCHEMBL2635791 0.60 CA2 (0.45) ARBRD4MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334637-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-01-04 EP disclosed
US-8372840-B2 Potassium channel blockers XENTION LIMITED (GB) 2013-02-12 US disclosed
US-20100087438-A1 New Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087438-A1 New Potassium Channel Blockers KCNJ2, KCNB1, KCNJ11 PARP10 1188/4885AR 1896/4885JAK2 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.